Susquehanna International Group’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-24,060
Closed -$10.8K 14145
2022
Q4
$10.8K Sell
24,060
-25,529
-51% -$10.6K ﹤0.01% 11926
2022
Q3
$24K Buy
49,589
+2,725
+6% +$1.34K ﹤0.01% 12544
2022
Q2
$23K Buy
46,864
+16,984
+57% +$8.22K ﹤0.01% 12337
2022
Q1
$18K Buy
29,880
+8,908
+42% +$4.67K ﹤0.01% 12659
2021
Q4
$14K Sell
20,972
-27,127
-56% -$48.4K ﹤0.01% 12892
2021
Q3
$165K Buy
+48,099
New +$150K ﹤0.01% 11709
2021
Q1
Sell
-32,253
Closed -$254K 13041
2020
Q4
$254K Buy
+32,253
New +$296K ﹤0.01% 9611

Other funds holding MTCR

Susquehanna International Group's MTCR Position: Q1 2023 in Review

Susquehanna International Group sold out of Metacrine, Inc. Common Stock (MTCR) in Q1 2023, closing a stake of 24,060 shares — an estimated $10.8K sold.

Susquehanna International Group first reported a position in MTCR in Q4 2020 and held it in 7 quarters. The position peaked at $254K in Q4 2020. 5 funds tracked by Wall St. Rank hold MTCR as of Q1 2023.

  • Susquehanna International Group reported no remaining Metacrine, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Susquehanna International Group sold 24,060 Metacrine, Inc. Common Stock shares in Q1 2023, an estimated $10.8K.
  • Susquehanna International Group first reported a position in Metacrine, Inc. Common Stock in Q4 2020 and held it in 7 quarters.
  • Susquehanna International Group's Metacrine, Inc. Common Stock position peaked at $254K in Q4 2020.
  • 5 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q1 2023.

Based on Susquehanna International Group's 13F filing for Q1 2023, filed 16 May 2023.